Literature DB >> 26877611

Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.

Ning Ding1, Li Che1, Xiao-Lei Li1, Yan Liu1, Li-Jie Jiang1, Biao Fan1, Jun-Yan Tao1, Xin Chen1, Jia-Fu Ji1.   

Abstract

AIM: To investigate whether IDH1R132C mutant in combination with loss of p53 and activated Notch signaling promotes intrahepatic cholangiocarcinoma (ICC) development.
METHODS: We applied hydrodynamic injection and sleeping beauty mediated somatic integration to induce loss of p53 (via shP53), activation of Notch [via intracellular domain of Notch1 (NICD)] and/or overexpression of IDH1R132C mutant together with the sleeping beauty transposase into the mouse liver. Specifically, we co-expressed shP53 and NICD (shP53/NICD, n = 4), shP53 and IDH1R132C (shP53/IDH1R132C, n = 3), NICD and IDH1R132C (NICD/IDH1R132C, n = 4), as well as NICD, shP53 and IDH1R132C (NICD/shP53/IDH1R132C, n = 9) in mice. Mice were monitored for liver tumor development and euthanized at various time points. Liver histology was analyzed by hematoxylin and eosin staining. Molecular features of NICD/shP53/IDH1R132C ICC tumor cells were characterized by Myc tag, Flag tag, Ki-67, p-Erk and p-AKT immunohistochemical staining. Desmoplastic reaction in tumor tissues was studied by Picro-Sirius red staining.
RESULTS: We found that co-expression of shP53/NICD, shP53/IDH1R132C or NICD/IDH1R132C did not lead to liver tumor formation. In striking contrast, co-expression of NICD/shP53/IDH1R132C resulted in ICC development in mice (P < 0.01). The tumors could be identified as early as 12 wk post hydrodynamic injection. Tumors rapidly progressed, and by 18 wk post hydrodynamic injection, multiple cystic lesions could be identified on the liver surface. NICD/shP53/IDH1R132C liver tumors shared multiple histological features of human ICCs, including hyperplasia of irregular glands. Importantly, all tumor cells were positive for the biliary epithelial cell marker cytokeratin 19. Extensive collagen fibers could be visualized in tumor tissues using Sirus red staining, duplicating the desmoplastic reaction observed in human ICC. Tumors were highly proliferative and expressed ectopically injected genes. Together these studies supported that NICD/shP53/IDH1R132C liver tumors were indeed ICCs. Finally, no p-AKT or p-ERK positive staining was observed, suggesting that NICD/shP53/IDH1R132C driven ICC development was independent of AKT/mTOR and Ras/MAPK signaling cascades.
CONCLUSION: We have generated a simple, non-germline murine ICC model with activated Notch, loss of p53 and IDH1R132C mutant. The study supported the oncogenic potential of IDH1R132C.

Entities:  

Keywords:  IDH1 mutant; Intrahepatic cholangiocarcinoma; Mouse liver cancer; Notch pathway; p53

Mesh:

Substances:

Year:  2016        PMID: 26877611      PMCID: PMC4726679          DOI: 10.3748/wjg.v22.i6.2071

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  47 in total

1.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

2.  Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration.

Authors:  Yann Malato; Syed Naqvi; Nina Schürmann; Raymond Ng; Bruce Wang; Joan Zape; Mark A Kay; Dirk Grimm; Holger Willenbring
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

Review 3.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

4.  KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.

Authors:  Maylee Hsu; Motoko Sasaki; Saya Igarashi; Yasunori Sato; Yasuni Nakanuma
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

5.  Exome sequencing of liver fluke-associated cholangiocarcinoma.

Authors:  Choon Kiat Ong; Chutima Subimerb; Chawalit Pairojkul; Sopit Wongkham; Ioana Cutcutache; Willie Yu; John R McPherson; George E Allen; Cedric Chuan Young Ng; Bernice Huimin Wong; Swe Swe Myint; Vikneswari Rajasegaran; Hong Lee Heng; Anna Gan; Zhi Jiang Zang; Yingting Wu; Jeanie Wu; Ming Hui Lee; DaChuan Huang; Pauline Ong; Waraporn Chan-on; Yun Cao; Chao-Nan Qian; Kiat Hon Lim; Aikseng Ooi; Karl Dykema; Kyle Furge; Veerapol Kukongviriyapan; Banchob Sripa; Chaisiri Wongkham; Puangrat Yongvanit; P Andrew Futreal; Vajarabhongsa Bhudhisawasdi; Steve Rozen; Patrick Tan; Bin Tean Teh
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

6.  Cholangiocarcinomas can originate from hepatocytes in mice.

Authors:  Biao Fan; Yann Malato; Diego F Calvisi; Syed Naqvi; Nataliya Razumilava; Silvia Ribback; Gregory J Gores; Frank Dombrowski; Matthias Evert; Xin Chen; Holger Willenbring
Journal:  J Clin Invest       Date:  2012-07-17       Impact factor: 14.808

7.  Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.

Authors:  P Wang; Q Dong; C Zhang; P-F Kuan; Y Liu; W R Jeck; J B Andersen; W Jiang; G L Savich; T-X Tan; J T Auman; J M Hoskins; A D Misher; C D Moser; S M Yourstone; J W Kim; K Cibulskis; G Getz; H V Hunt; S S Thorgeirsson; L R Roberts; D Ye; K-L Guan; Y Xiong; L-X Qin; D Y Chiang
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 8.756

8.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Authors:  Darrell R Borger; Kenneth K Tanabe; Kenneth C Fan; Hector U Lopez; Valeria R Fantin; Kimberly S Straley; David P Schenkein; Aram F Hezel; Marek Ancukiewicz; Hannah M Liebman; Eunice L Kwak; Jeffrey W Clark; David P Ryan; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Andrew X Zhu; A John Iafrate
Journal:  Oncologist       Date:  2011-12-16       Impact factor: 5.837

9.  Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.

Authors:  M Fernanda Amary; Stephen Damato; Dina Halai; Malihe Eskandarpour; Fitim Berisha; Fiona Bonar; Stan McCarthy; Valeria R Fantin; Kimberly S Straley; Samira Lobo; Will Aston; Claire L Green; Rosemary E Gale; Roberto Tirabosco; Andrew Futreal; Peter Campbell; Nadège Presneau; Adrienne M Flanagan
Journal:  Nat Genet       Date:  2011-11-06       Impact factor: 41.307

10.  CpG-island methylation study of liver fluke-related cholangiocarcinoma.

Authors:  R Sriraksa; C Zeller; M A El-Bahrawy; W Dai; J Daduang; P Jearanaikoon; S Chau-In; R Brown; T Limpaiboon
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

View more
  4 in total

Review 1.  The implications of IDH mutations for cancer development and therapy.

Authors:  Christopher J Pirozzi; Hai Yan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

2.  Identification of a Pan-Gamma-Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma.

Authors:  Colm J O'Rourke; Matthias S Matter; Chirag Nepal; Rui Caetano-Oliveira; Phuongnga T Ton; Valentina M Factor; Jesper B Andersen
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.298

Review 3.  IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives.

Authors:  Fabiana Crispo; Michele Pietrafesa; Valentina Condelli; Francesca Maddalena; Giuseppina Bruno; Annamaria Piscazzi; Alessandro Sgambato; Franca Esposito; Matteo Landriscina
Journal:  Molecules       Date:  2020-08-18       Impact factor: 4.411

Review 4.  Notch signaling in the pathogenesis, progression and identification of potential targets for cholangiocarcinoma (Review).

Authors:  Peeranate Vanaroj; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Mol Clin Oncol       Date:  2022-01-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.